US Approves Generic Lénacapavir for HIV Prevention

The US Food and Drug Administration has approved the first generic version of lenacapavir, a twice-yearly injectable HIV prevention drug, opening access for low- and middle-income countries at $40 per person annually. Le Monde.fr reported that Dr. Reddy’s Laboratories issued the announcement on November 2, 2026, following an exceptionally rapid regulatory review.

The new generic treatment delivers a preventative efficacy approaching 100%, according to Unitaid. Unlike oral PrEP medications requiring daily pills, lenacapavir requires two injections per year. Gilead Sciences originally developed the drug under the brand name Yeztugo, securing FDA approval in June 2025 before partnering on voluntary licensing agreements.

Regulatory Approval Achieved in Sixteen Months

The generic authorization arrived just sixteen months after the original drug’s approval, bypassing traditional decade-long lag periods for developing nations. Unitaid noted that regulatory innovation and proactive licensing terms drove the speed of the rollout. Carmen Pérez-Casas, Unitaid’s senior HIV strategy manager, told Agence France-Presse that shrinking the transition timeline from ten years to just over one year represents a major public health milestone.

Dr. Reddy’s Laboratories secured tentative FDA approval to supply the medication across 120 low- and middle-income countries. Initial shipments are scheduled to reach clinics before the end of 2026, with broader distribution scaling through 2027. Unitaid reported that more than 125,000 individuals in Africa have already initiated lenacapavir regimens.

Pricing Matched to Oral PrEP Removes Financial Barriers

The negotiated price point of $40 (roughly 36 euros) per person annually aligns closely with traditional oral PrEP costs, removing the financial barriers that kept the original Gilead product out of reach for resource-limited health systems. Unitaid emphasized that reliable supply chains and willing healthcare providers remain critical to deploying the injections at scale.

In France, where the treatment was authorized in Europe in August 2025 under the brand name Yeytuo, early recipients describe the transition from daily pills to semiannual injections as a profound relief from daily pill fatigue.